VitiligoNCT07907744
Plasma Exeresis Plus NB-UVB Versus NB-UVB Alone for Stable Vitiligo
A study testing Plasma Exeresis and Narrowband Ultraviolet B (NB-UVB) Phototherapy in people with Vitiligo, run by University of Faisalabad at 1 site in Pakistan.
Trial summary
The goal of this quasi-experimental clinical trial is to compare the effectiveness of plasma exeresis combined with narrowband ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in patients with stable non-segmental vitiligo aged 8 to 65 years. Read more about this study
- Who is it for?
- Ages 8 to 65 years
- Conditions the study is for
- Vitiligo
- What is being tested?
- Plasma Exeresis and Narrowband Ultraviolet B (NB-UVB) Phototherapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jan 2025to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Both male and female participants.
- Age 8-65 years.
- Diagnosis of non-segmental stable vitiligo.
- Vitiligo lesions located in areas accessible for treatment.
Who cannot join
- Lesions involving the face or scalp.
- Pregnant or lactating women.
- History of photosensitivity or skin cancer.
- Receipt of other vitiligo treatment within the preceding 1 month.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Plasma Exeresis and Narrowband Ultraviolet B (NB-UVB) Versus NB-UVB Monotherapy in the Treatment of Vitiligo: A Quasi-Experimental Study
The goal of this quasi-experimental clinical trial is to compare the effectiveness of plasma exeresis combined with narrowband ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in patients with stable non-segmental vitiligo aged 8 to 65 years.
The main questions it aims to answer are:
Read more
- Does plasma exeresis combined with NB-UVB produce greater repigmentation than NB-UVB alone after 24 weeks?
- Is combination therapy associated with better clinical response as measured by the Vitiligo Area Scoring Index (VASI)?
Researchers will compare plasma exeresis plus NB-UVB with NB-UVB alone to determine whether the combination treatment improves repigmentation.
Participants will:
- Receive either plasma exeresis once monthly plus NB-UVB twice weekly, or NB-UVB phototherapy alone twice weekly.
- Attend follow-up visits every 4 weeks for 24 weeks.
- Have their vitiligo severity assessed using the Vitiligo Area Scoring Index (VASI) at baseline and during follow-up.
Read the detailed description
Vitiligo is an acquired depigmenting disorder characterized by the loss of functional melanocytes and has a substantial psychosocial impact. Narrowband ultraviolet B (NB-UVB) phototherapy is an established treatment for stable non-segmental vitiligo; however, repigmentation is often gradual and incomplete.
This quasi-experimental study will evaluate whether the addition of plasma exeresis enhances the therapeutic efficacy of NB-UVB phototherapy. Seventy patients with stable non-segmental vitiligo will be allocated into two treatment groups. Group A will receive plasma exeresis once monthly in combination with NB-UVB phototherapy twice weekly, while Group B will receive NB-UVB phototherapy alone twice weekly. Participants will be followed for 24 weeks with clinical assessments every four weeks.
The primary outcome is the change in Vitiligo Area Scoring Index (VASI) from baseline to week 24. The findings of this study are expected to provide evidence regarding the comparative effectiveness of combination therapy versus NB-UVB monotherapy in the management of stable vitiligo.
- Conditions
- Vitiligo
- Being tested
- Plasma Exeresis, Narrowband Ultraviolet B (NB-UVB) Phototherapy
- Keywords
- Vitiligo, Non-segmental vitiligo, Stable vitiligo, Plasma exeresis, Narrowband ultraviolet B, NB-UVB, Phototherapy, Repigmentation, Vitiligo Area Scoring Index, VASI
- Medical subject headings
- Vitiligo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Plasma ExeresisProcedure or surgery
Plasma exeresis is performed once monthly using a handheld device. The procedure involves controlled treatment of depigmented vitiligo lesions with localized thermal injury to stimulate repigmentation.
Narrowband Ultraviolet B (NB-UVB) PhototherapyRadiation
Narrowband ultraviolet B (NB-UVB) phototherapy is administered twice weekly for 24 weeks for the treatment of stable non-segmental vitiligo.
| Study group | Role | What they receive |
|---|---|---|
| Plasma Exeresis + NB-UVB | Experimental | Participants in this arm receive plasma exeresis once monthly combined with narrowband ultraviolet B (NB-UVB) phototherapy twice weekly for 24 weeks. Participants are assessed every 4 weeks, and treatment response is evaluated using the Vitiligo Area Scoring Index (VASI). Receives: Procedure: Plasma Exeresis; Radiation: Narrowband Ultraviolet B (NB-UVB) Phototherapy |
| NB-UVB alone | Active comparator | Participants in this arm receive narrowband ultraviolet B (NB-UVB) phototherapy twice weekly for 24 weeks. Participants are assessed every 4 weeks, and treatment response is evaluated using the Vitiligo Area Scoring Index (VASI). Receives: Radiation: Narrowband Ultraviolet B (NB-UVB) Phototherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Vitiligo Area Scoring Index (VASI) from Baseline to Week 24
Treatment efficacy will be assessed by measuring the change in Vitiligo Area Scoring Index (VASI) from baseline to Week 24. A reduction of 50% or more in VASI score after 24 weeks will be considered a clinically significant improvement, indicating effective treatment.
Measured: Baseline to Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2026
- Study start1 Jan 2025
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for VitiligoStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This is a quasi-experimental, two-arm, parallel-group study. Participants are assigned to either Group A, receiving plasma exeresis once monthly combined with NB-UVB phototherapy twice weekly, or Group B, receiving NB-UVB phototherapy twice weekly alone. Participants are followed for 24 weeks, with VASI assessed at baseline and every 4 weeks.
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Faisalabad
- Sponsor type
- University, hospital or other
- Collaborators
- Madina Teaching Hospital Faisalabad
- Responsible party
- Sponsor
- Investigators
- Tanzeela Khalid, MBBS, FCPS Dermatology, Study director, The University of Faisalabad
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07907744
- Sponsor's protocol ID
- TUF/IRB/471/24
- Status last verified
- Oct 2026
- First submitted
- 25 Oct 2026
- Last updated
- 30 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Plasma Exeresis and Narrowband Ultraviolet B (NB-UVB) Versus NB-UVB Monotherapy in the Treatment of Vitiligo: A Quasi-Experimental Study
- ClinicalTrials.gov ID
- NCT07907744
- Acronym / sponsor ID
- TUF/IRB/471/24
- Conditions
- Vitiligo
- Keywords
- Vitiligo, Non-segmental vitiligo, Stable vitiligo, Plasma exeresis, Narrowband ultraviolet B, NB-UVB, Phototherapy, Repigmentation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 70 participants (actual)
- Lead sponsor
- University of FaisalabadUniversity, hospital or other
- Collaborators
- Madina Teaching Hospital Faisalabad
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 30 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this quasi-experimental clinical trial is to compare the effectiveness of plasma exeresis combined with narrowband ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in patients with stable non-segmental vitiligo aged 8 to 65 years.
The main questions it aims to answer are:
- Does plasma exeresis combined with NB-UVB produce greater repigmentation than NB-UVB alone after 24 weeks?
- Is combination therapy associated with better clinical response as measured by the Vitiligo Area Scoring Index (VASI)?
Researchers will compare plasma exeresis plus NB-UVB with NB-UVB alone to determine whether the combination treatment improves repigmentation.
Participants will:
- Receive either plasma exeresis once monthly plus NB-UVB twice weekly, or NB-UVB phototherapy alone twice weekly.
- Attend follow-up visits every 4 weeks for 24 weeks.
- Have their vitiligo severity assessed using the Vitiligo Area Scoring Index (VASI) at baseline and during follow-up.
Detailed description
Vitiligo is an acquired depigmenting disorder characterized by the loss of functional melanocytes and has a substantial psychosocial impact. Narrowband ultraviolet B (NB-UVB) phototherapy is an established treatment for stable non-segmental vitiligo; however, repigmentation is often gradual and incomplete.
This quasi-experimental study will evaluate whether the addition of plasma exeresis enhances the therapeutic efficacy of NB-UVB phototherapy. Seventy patients with stable non-segmental vitiligo will be allocated into two treatment groups. Group A will receive plasma exeresis once monthly in combination with NB-UVB phototherapy twice weekly, while Group B will receive NB-UVB phototherapy alone twice weekly. Participants will be followed for 24 weeks with clinical assessments every four weeks.
The primary outcome is the change in Vitiligo Area Scoring Index (VASI) from baseline to week 24. The findings of this study are expected to provide evidence regarding the comparative effectiveness of combination therapy versus NB-UVB monotherapy in the management of stable vitiligo.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a quasi-experimental, two-arm, parallel-group study. Participants are assigned to either Group A, receiving plasma exeresis once monthly combined with NB-UVB phototherapy twice weekly, or Group B, receiving NB-UVB phototherapy twice weekly alone. Participants are followed for 24 weeks, with VASI assessed at baseline and every 4 weeks.
| Arm | Type | Receives |
|---|---|---|
| Plasma Exeresis + NB-UVB | Experimental | Procedure: Plasma Exeresis, Radiation: Narrowband Ultraviolet B (NB-UVB) PhototherapyParticipants in this arm receive plasma exeresis once monthly combined with narrowband ultraviolet B (NB-UVB) phototherapy twice weekly for 24 weeks. Participants are assessed every 4 weeks, and treatment response is evaluated using the Vitiligo Area Scoring Index (VASI). |
| NB-UVB alone | Active comparator | Radiation: Narrowband Ultraviolet B (NB-UVB) PhototherapyParticipants in this arm receive narrowband ultraviolet B (NB-UVB) phototherapy twice weekly for 24 weeks. Participants are assessed every 4 weeks, and treatment response is evaluated using the Vitiligo Area Scoring Index (VASI). |
Who may qualify
- Ages
- 8 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Both male and female participants.
- Age 8-65 years.
- Diagnosis of non-segmental stable vitiligo.
- Vitiligo lesions located in areas accessible for treatment.
Key exclusion criteria (4 listed)
- Lesions involving the face or scalp.
- Pregnant or lactating women.
- History of photosensitivity or skin cancer.
- Receipt of other vitiligo treatment within the preceding 1 month.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Plasma ExeresisPlasma exeresis is performed once monthly using a handheld device. The procedure involves controlled treatment of depigmented vitiligo lesions with localized thermal injury to stimulate repigmentation. | Procedure or surgery | Plasma Exeresis + NB-UVB |
| Narrowband Ultraviolet B (NB-UVB) PhototherapyNarrowband ultraviolet B (NB-UVB) phototherapy is administered twice weekly for 24 weeks for the treatment of stable non-segmental vitiligo. | Radiation | NB-UVB alone, Plasma Exeresis + NB-UVB |
Primary outcome
Change in Vitiligo Area Scoring Index (VASI) from Baseline to Week 24
Time frame: Baseline to Week 24
Treatment efficacy will be assessed by measuring the change in Vitiligo Area Scoring Index (VASI) from baseline to Week 24. A reduction of 50% or more in VASI score after 24 weeks will be considered a clinically significant improvement, indicating effective treatment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
Related trials for Vitiligo
RecruitingPhase 3
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
Vitiligo, Non-Segmental Vitiligo (NSV)
RecruitingPhase 1
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Vitiligo
RecruitingPhase 2
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
Non-Segmental Vitiligo (NSV)
Not yet recruitingPhase 3
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Non-Segmental Vitiligo
Active, not recruitingPhase 1
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
Vitiligo
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tanzeela Khalid, MBBS, FCPS Dermatology study director
The University of Faisalabad
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Plasma Exeresis and Narrowband Ultraviolet B (NB-UVB) Phototherapy in people with Vitiligo, run by University of Faisalabad at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Vitiligo Area Scoring Index (VASI) from Baseline to Week 24 (time frame: Baseline to Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.